Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | GCLC | P48506 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001780 | 1.00 | PMP22 (0.70) | PMP22GCLCNOS2SLC7A5 | |
| SCHEMBL8594079 | 0.83 | PMP22 (1.00) | PMP22GCLCNOS2SLC7A5 | |
| SCHEMBL187872 | 0.83 | PMP22 (1.00) | PMP22GCLCNOS2SLC7A5 | |
| SCHEMBL187873 | 0.83 | PMP22 (1.00) | PMP22GCLCNOS2SLC7A5 | |
| SCHEMBL1347918 | 0.83 | PMP22 (1.00) | PMP22GCLCNOS2SLC7A5 | |
| Ammonia Solution, Strong SCHEMBL16912221 | 0.81 | PMP22 (0.96) | PMP22GCLCNOS2SLC7A5 | |
| SCHEMBL22137488 | 0.78 | PMP22 (0.53) | PMP22 | |
| Phosphoric Acid SCHEMBL4258425 | 0.76 | PMP22 (0.85) | PMP22GCLC | |
| SCHEMBL1920080 | 0.76 | PMP22 (0.41) | PMP22GCLCNOS2 | |
| SCHEMBL14089773 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170181994-A1 | Use Of Methionine Sulfoximine To Treat Diseases Caused By An Inflammatory Cytokine Response | BRUSILOW, WILLIAM | 2017-06-29 | — | — | US | disclosed |
| US-9561203-B2 | Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response | BRUSILOW, WILLIAM | 2017-02-07 | — | — | US | disclosed |
| US-20160081958-A1 | USE OF METHIONINE SULFOXIMINE TO TREAT DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE | BRUSILOW, WILLIAM | 2016-03-24 | — | — | US | disclosed |
| US-9119821-B2 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response | BERNARDI, PAOLO (IT) | 2015-09-01 | — | — | US | disclosed |
| US-20140121277-A1 | USE OF METHIONINE SULFOXIMINE TO TREAT ACUTE LIVER FAILURE AND OTHER DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE | BRUSILOW, WILLIAM | 2014-05-01 | — | — | US | disclosed |
| US-8530515-B2 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response | BERNARDI, PAOLO (IT) | 2013-09-10 | — | — | US | disclosed |
| US-20120035264-A1 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response | BERNARDI, PAOLO (IT) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035264-A1 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response | MTR, MSRB3, DDO | PMP22 4028/4885GCLC 240/4885NOS2 294/4885 |
| US-20160081958-A1 | USE OF METHIONINE SULFOXIMINE TO TREAT DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE | MTR, MSRB3, IFNG | PMP22 4111/4885GCLC 125/4885NOS2 303/4885 |
| US-20140121277-A1 | USE OF METHIONINE SULFOXIMINE TO TREAT ACUTE LIVER FAILURE AND OTHER DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE | MTR, MSRB3, DDO | PMP22 4028/4885GCLC 240/4885NOS2 294/4885 |
| US-20170181994-A1 | Use Of Methionine Sulfoximine To Treat Diseases Caused By An Inflammatory Cytokine Response | MTR, MSRB3, IFNG | PMP22 4111/4885GCLC 125/4885NOS2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.